Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a vaccine protect spleen injury patients from deadly infections?

NCT ID NCT02232191

Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 19, 2026 · Updated 3 times

Summary

People without a working spleen are at high risk of severe infections from pneumococcus bacteria. This study looks at how well the pneumococcal vaccine works in adults aged 18-65 who have a spleen injury and are treated with monitoring, embolization, or spleen removal. Researchers will measure antibody levels to see which treatment approach leads to the best immune response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pneumovax-23 (pneumococcal polysaccharide vaccine)
What this could lead to
If successful, this could help doctors choose the best treatment for spleen injuries to maximize vaccine protection against serious infections.
What could go wrong
This is a small Phase 2 study with only 75 participants, so results may not apply to everyone. The vaccine may not provide full protection, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Dec 2014

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury. Exclusion Criteria: * Ages less than 18 and greater than 65 * Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asplenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial isolated congenital asplenia pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asplenia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, Davis Medical Center

    RECRUITING

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.